ArticleAdvances in radiation oncology2026
Incremental Value of Radiation Dose for Prognostic Stratification Beyond Performance Status in Palliative Radiation Therapy for Bone Metastases.
Article in Advances in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Although the individual prognostic value of performance status (PS) and prescribed dose for overall survival (OS) in palliative radiation therapy for bone metastases has been investigated, their combined prognostic significance has not been thoroughly explored. This study aimed to evaluate the combined prognostic value of PS and prescribed dose for OS in patients with bone metastases undergoing palliative radiation therapy. Methods and Materials: This study included 423 patients who underwent palliative radiation therapy for bone metastases between January 2013 and October 2024. The primary endpoint was OS, evaluated at fixed follow-up points of 1, 3, and 6 months, as well as 1, 2, and 3 years. Results: Univariate Cox regression analysis demonstrated that 1-year OS was significantly associated with poor PS (hazard ratio, 2.6 [95% CI, 2.2-3.1]; Conclusions: Combining PS and prescribed dose enabled more refined risk stratification for predicting short- and long-term OS in patients with bone metastases undergoing palliative radiation therapy, regardless of primary tumor risk classification or the number of distant metastases. Moreover, adding prescribed dose to PS provided significant incremental predictive value for OS in this setting.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.